Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Illumina in Acquisition of Verinata Health

January 7, 2013

NEW YORK, January 7, 2013 — Covington & Burling advised Illumina, Inc. on its announced acquisition of Verinata Health, Inc. for cash consideration of $350 million plus up to $100 million in milestone payments through 2015.

Upon completion of the acquisition, Illumina will have access to the Verinata’s verifi® prenatal test, the broadest non-invasive prenatal test available today for high-risk pregnancies, and to the most comprehensive intellectual property portfolio in the non-invasive prenatal test industry.

Covington’s team was led Jack Bodner, with assistance from Scott Smith, and associates Dan Levine and Larry Bartenev. The team also included Peter Schwartz and Ira Palgon (financing), Rob Heller (tax), Ellen Corenswet (venture capital), Bruce Deming and Scott Anthony (California corporate and employment matters), Ben Hoch (bankruptcy), Mike Francese and Will Woolston (benefits), Scott Danzis and Peter Safir (regulatory), Keir Gumbs (securities), and Jessica Milner (IP).

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Verinata is a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities.

Share this article: